Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trial
APRE•Phase 1 trial update and enrollment plans
Aprea Therapeutics outlined plans to accelerate enrollment in its Phase 1 ACESOT-1051 dose-escalation trial of WEE1 inhibitor APR-1051.
Early single-agent activity was observed with a favorable tolerability profile, without reporting detailed efficacy or safety metrics.
Next clinical results are scheduled for presentation at a medical meeting in Q4 2026.
Development focus and planned combination arms
Development focus shifts toward uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, supported by an expansion to at least 50 patients.
New combination arms are planned in HPV-positive head and neck cancer and colorectal cancer, using dose levels that have already cleared safety review.
